The incidence of ischemic stroke - Paroxysmal af vs persistent/permanent Af

Circulation Journal

Volumn 73, Issue 8, 2009, Pages 1393-1394

  Koretsune, Yukihiro ^a  

^a OSAKA NATIONAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; WARFARIN;

ANTICOAGULANT THERAPY; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; EDITORIAL; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; PAROXYSMAL HEART ATRIUM FIBRILLATION; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; INCIDENCE; STROKE; THROMBOEMBOLISM;

EID: 69049110109     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0440     Document Type: Editorial

References (14)

1. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: Executive summary. Circulation 2006; 114: 700-752.
2. Ogawa S, Aizawa Y, Koretsune Y, Sugi K, Atarashi H, Inoue H, et al. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008). Circ J 2008; 72(Suppl IV): 1581-1658.
3. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation incidence and predictors during aspirin therapy: Stroke prevention in atrial fibrillation investigators. J Am Coll Cardiol 2000; 35: 183-187.
4. Capucci A, Santini M, Padeletti L, Gulizia M, Botto G, Boriani G, et al, for the Italian AT500 Registry Investigators. Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol 2005; 46: 1913-1920.
5. Wyse BG. Anticoagulation in atrial fibrillation: A contemporary viewpoint. Heart Rhythm 2007; 4: 534-539.
6. Israel CW, Gronefeld G, Ehrlich JR, Li YG, Hohnloser SH. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device. J Am Coll Cardiol 2004; 43: 47-52.
7. Manning WJ, Silverman DI, Waksmonski CA, Oettgen P, Douglas PS. Prevalence of residual left atrial thrombi among patients with acute thromboembolism and newly recognized atrial fibrillation. Arch Intern Med 1995; 155: 2193-2198.
8. Hohnloser SH, Pajitnev D, Pogue J, Healey JS, Pfeffer MA, Yusuf S, et al, for the ACTIVE W Investigators. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anti-coagulation or combined antiplatelet therapy. J Am Coll Cardiol 2007; 50: 2156-2161.
9. Motoki H, Tomita T, Aizawa K, Kasai H, Izaka A, Kumazaki S, et al. Coagulation activity is increased in the left atria of patients with paroxysmal atrial fibrillation during the non-paroxysmal period: Comparison with chronic atrial fibrillation. Circ J 2009; 73: 1403-1407.
10. Grimm RA, Leung DY, Black IW, Stewart WJ, Thomas JD, Klein AL. Left atrial appendage "stunning" after spontaneous cardioversion in patients with atrial fibrillation demonstrated by transesophageal Doppler echocardiography. Am Heart J 1995; 130: 174-176.
11. Klein AL, Murray RD, Grimm RA. Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation. JAm Coll Cardiol 2001; 37: 691-704. (Pubitemid 32202432)
12. Khan IA. Atrial stunning: Determinants and cellular mechanisms. Am Heart J 2003; 145: 787-794.
13. Dunn MI, Marcum JL. Atrial mechanical performance following internal and external cardioversion of atrial fibrillation: Its relationship to peripheral embolization and acute cerebrovascular accident. Chest 2002; 121: 1-3.
14. Stoddard MF, Dawkins PR, Prince CR, Longaker RA. Transesophageal echocardiographic guidance of cardioversion in patients with atrial fibrillation. Am Heart J 1995; 129: 1204-1215.